{"product_id":"innovage-pestle-analysis","title":"InnovAge PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Competitive Advantage Starts with This Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political shifts, economic pressures, and technological trends are reshaping InnovAge’s prospects in our concise PESTLE snapshot—built for investors and strategists who need fast, actionable context. Purchase the full PESTLE to unlock detailed risk assessments, regulatory timelines, and market signals you can use immediately to inform decisions and spot growth opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFederal Support for the PACE Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe federal government continues to promote the Program of All-inclusive Care for the Elderly as a cost-effective alternative to nursing homes; Medicare\/Medicaid estimates show PACE average annual per-participant costs 20–30% lower than institutional care as of 2024. By end-2025 streamlined federal legislation reduced application time for new PACE centers by roughly 40%, enabling InnovAge to pursue expansion across its multi-state footprint with clearer reimbursement pathways and predictable regulatory support.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eState-Level Medicaid Expansion and Policy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIndividual state governments set PACE eligibility and enrollment caps via Medicaid contracts; as of 2024, 32 states plus DC have active PACE programs with enrollment growth averaging 7% yr\/yr, but state-level caps limit scale in several large markets.\u003c\/p\u003e\n\u003cp\u003ePolitical shifts can increase funding or tighten budgets—for example, 2023–24 state Medicaid shortfalls led six states to consider rate reductions averaging 3–5%, directly affecting InnovAge reimbursement.\u003c\/p\u003e\n\u003cp\u003eInnovAge must sustain relationships with state health departments and legislators to influence policy, secure waivers, and pursue waiver expansions that could unlock millions in additional annual Medicaid revenue per state.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Oversight by CMS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Centers for Medicare and Medicaid Services enforces rigorous oversight of InnovAge, with CMS quality-star metrics and audits driving compliance; InnovAge must meet Medicare Advantage and CHHA benchmarks tied to reimbursement—CMS imposed 2024 penalty rates and reimbursement adjustments averaged 1.5–3% across comparable programs. \u003c\/p\u003e\n\u003cp\u003eHeightened political focus on senior outcomes has increased audit frequency; CMS conducted a 22% rise in program integrity reviews for value-based care providers in 2023–24, prompting stricter reporting and documentation requirements for InnovAge. \u003c\/p\u003e\n\u003cp\u003eProactive compliance is critical: failure to meet CMS mandates risks sanctions, payment caps, or license actions—CMS enforcement actions led to average provider revenue losses of 4–6% in 2023, underscoring the financial imperative for InnovAge to stay ahead. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBipartisan Focus on Aging in Place\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThere is bipartisan support for aging in place, reflected in CMS funding increases for home- and community-based services which rose by about 7% in 2024, reducing policy volatility that could threaten InnovAge’s PACE model.\u003c\/p\u003e\n\u003cp\u003ePolicy alignment enables InnovAge to pursue multi-year capital projects and partnerships; stable reimbursement trends (Medicaid HCBS spending reached roughly $120B in 2024) support predictable cash flows.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBipartisan consensus lowers regulatory risk\u003c\/li\u003e\n\u003cli\u003eHCBS spending ~ $120B (2024) aids predictability\u003c\/li\u003e\n\u003cli\u003eCMS\/Home funding +7% (2024) supports long-term investment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Reform and Policy Uncertainty\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOngoing debates over the Affordable Care Act and Medicare policy create uncertainty for providers; in 2024 federal healthcare spending reached about $1.9 trillion and proposed reforms could reallocate millions in value-based care incentives affecting InnovAge.\u003c\/p\u003e\n\u003cp\u003eShifts in federal administration often change priorities for integrated care models—CMS increased Medicare Advantage enrollment to 48% of beneficiaries in 2023, illustrating how policy focus alters market demand and funding streams.\u003c\/p\u003e\n\u003cp\u003eInnovAge must stay agile, scenario-plan for changes to national insurance structures, and monitor legislative actions that could impact revenue tied to bundled payments and value-based contracts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 federal healthcare spend ≈ $1.9T;\u003c\/li\u003e\n\u003cli\u003eMedicare Advantage enrollment 48% (2023);\u003c\/li\u003e\n\u003cli\u003eRisk: shifts in value-based funding and bundled payment allocations;\u003c\/li\u003e\n\u003cli\u003eAction: scenario planning and policy monitoring.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising HCBS Funding \u0026amp; PACE Growth Amid Heightened CMS Audits—InnovAge Must Prioritize Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFederal support for PACE and HCBS rose in 2024—CMS HCBS funding +7% and Medicaid HCBS spending ≈ $120B—while 32 states+DC run PACE with ~7% annual enrollment growth; CMS audits increased 22% (2023–24) and enforcement trimmed provider revenues 4–6% (2023). InnovAge faces state caps, proposed Medicaid rate cuts (3–5%) and must prioritize compliance and policy engagement.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2023–24 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStates with PACE\u003c\/td\u003e\n\u003ctd\u003e32+DC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePACE enrollment growth\u003c\/td\u003e\n\u003ctd\u003e~7% yr\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHCBS spend\u003c\/td\u003e\n\u003ctd\u003e$120B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMS audits rise\u003c\/td\u003e\n\u003ctd\u003e+22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProvider revenue loss (avg)\u003c\/td\u003e\n\u003ctd\u003e4–6% (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect InnovAge across six dimensions—Political, Economic, Social, Technological, Environmental, and Legal—backed by relevant data and current trends to reveal threats and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise InnovAge PESTLE summary that distills regulatory, economic, social, technological, environmental, and legal insights for quick inclusion in presentations or strategy sessions, easily editable for local context and shareable across teams to streamline risk discussions and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising Labor Costs and Healthcare Staffing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe U.S. home health and nursing labor market shows persistent shortages: Bureau of Labor Statistics data to 2024 indicate a 12% annual wage growth in home health aide roles in some regions and median RN wages up ~8% since 2021; InnovAge must raise compensation to compete, or face turnover that undermines care quality. Rising personnel costs—representing often 60–70% of operating expenses—can compress margins unless Medicare\/Medicaid reimbursement increases offset higher payroll burdens.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare and Medicaid Reimbursement Rates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInnovAge depends on capitated Medicare\/Medicaid payments—about 70% of revenue in 2024—so CMS annual rate updates are material; the 2024 Medicare Advantage rebate adjustments and 2025 proposed rate pressures risk lower per-member-per-month (PMPM) revenue.\u003c\/p\u003e\n\u003cp\u003eEconomic downturns or federal deficit-cutting could cap or cut rates; a 1% CMS rate reduction would shave several percentage points off InnovAge’s 2024-25 revenue growth given fixed-payment models.\u003c\/p\u003e\n\u003cp\u003eManagement must drive cost per member down—InnovAge reported ~$X,XXX PMPM operating costs in 2024—improving care management and reducing hospitalizations to protect margins within capitated payments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary Pressures on Medical Supplies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInflation drove medical equipment, prescription drugs and personal care supplies up sharply through 2025, with US healthcare goods inflation averaging about 6.2% in 2024–2025 and drug prices up roughly 5–7% annually. These rising input costs force InnovAge to pursue strategic sourcing, supplier consolidation and bulk purchasing to preserve margins. Controlling supply-chain expenses is essential to sustain InnovAge’s comprehensive care model and avoid service-quality tradeoffs. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost Savings of Preventive Care Models\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe PACE model reduces costs by preventing hospitalizations and nursing-home placements; InnovAge reports average annual savings of roughly $9,000–$12,000 per participant versus fee-for-service Medicaid\/Medicare mixes (2023–2024 internal and state evaluations). By coordinating care and managing chronic conditions, InnovAge lowers total cost of care and admission rates, making it an attractive partner for state Medicaid programs and managed-care payers.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAverage savings per participant: $9,000–$12,000 (2023–2024)\u003c\/li\u003e\n\u003cli\u003eReduced hospital admission and nursing-home days vs. FFS\u003c\/li\u003e\n\u003cli\u003eSupports state Medicaid cost-containment and partnership deals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital Market Conditions and Expansion Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAccess to affordable capital is critical for InnovAge to build new centers and upgrade facilities; U.S. commercial real estate lending fell 9% in 2024 while BBB corporate bond spreads averaged ~160 bps, affecting borrowing costs.\u003c\/p\u003e\n\u003cp\u003eInterest-rate volatility—Fed funds ranged 5.25–5.50% in 2024—increases debt service and can compress valuations, forcing slower rollout of new sites.\u003c\/p\u003e\n\u003cp\u003eWhen GDP growth and credit conditions are favorable, InnovAge can pursue aggressive expansion; in high-rate environments, management may defer projects or use lease\/partnership models to limit capex.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 Fed funds 5.25–5.50%\u003c\/li\u003e\n\u003cli\u003eBBB spreads ~160 bps in 2024\u003c\/li\u003e\n\u003cli\u003eUS CRE lending -9% (2024)\u003c\/li\u003e\n\u003cli\u003ePrefer lease\/partnerships if rates stay elevated\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising wages, inflation \u0026amp; Medicare pressure threaten margins despite $9k–$12k PACE savings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLabor shortages and 2024 wage inflation (home health aides +12% in some regions; RNs +8% since 2021) raise payroll (60–70% of costs); capitated Medicare\/Medicaid (~70% revenue) faces rate pressure (2024 MA rebate changes; potential 1% CMS cut impact material). Medical goods inflation ~6.2% (2024–25); average PACE savings $9k–$12k\/participant (2023–24).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024–25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHome health aide wage growth\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRN wage change since 2021\u003c\/td\u003e\n\u003ctd\u003e+8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue from Medicare\/Medicaid\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare goods inflation\u003c\/td\u003e\n\u003ctd\u003e~6.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePACE savings\/participant\u003c\/td\u003e\n\u003ctd\u003e$9k–$12k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eInnovAge PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact InnovAge PESTLE Analysis document you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751331148153,"sku":"innovage-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/innovage-pestle-analysis.png?v=1772230223","url":"https:\/\/growthsharematrix.com\/products\/innovage-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}